KEENSEA Medical Technology recently announced that its wholly-owned subsidiary, KEENSEA Xiehuan, has recently entered into a general sales agreement with Sinopharm LingShang. Under this agreement, KEENSEA Xiehuan has granted Sinopharm LingShang the exclusive distributorship for several of the Group's high-end medical devices in China, with the term extending to October of this year. Leveraging Sinopharm LingShang's extensive distribution network and strong market influence, the Group's main products are expected to gain visibility in a broader market, achieving rapid growth. In particular, the Group's 4K 3D fluorescence endoscope, percutaneous endoscopic lumbar discectomy (PELD) endoscope, and related instrument packs have demonstrated strong market competitiveness and growth potential.In the first half of 2024, KEENSEA Medical Technology achieved revenue of 25.937 million Singapore dollars, an increase of 116.45% year-on-year. Revenue from minimally invasive surgical solutions, medical products, and related service fees increased from 0.4 million Singapore dollars in the first half of 2023 to 12.3 million Singapore dollars in the first half of 2024. In terms of technological reserves, KEENSEA Medical Technology holds over 60 patents, more than 20 trademarks, and has over 30 ongoing research and development projects. In the "Minimally Invasive 4.0 Era," KEENSEA Medical Technology is comprehensively leading in basic technologies, with existing capabilities including three/four-chip, naked-eye 3D, 4K, 3D, and fluorescence technologies.